Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer

International Journal of Clinical Oncology

Volumn 20, Issue 3, 2015, Pages 605-612

  Shigeta, Keisuke ^a   Kosaka, Takeo ^a   Yazawa, Satoshi ^a   Yasumizu, Yota ^a   Mizuno, Ryuichi ^a   Nagata, Hirohiko ^a   Shinoda, Kazunobu ^a   Morita, Shinya ^a   Miyajima, Akira ^a   Kikuchi, Eiji ^a   Nakagawa, Ken ^a   Hasegawa, Shintaro ^a,b   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization Tochigi Medical Center   (Japan)

Author keywords

Castration resistant prostate cancer; Docetaxel; Febrile neutropenia; Predictive factor; Severe neutropenia

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

AGED; ALOPECIA; ANOREXIA; ARTICLE; BODY TEMPERATURE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMORBIDITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT HISTORY OF RADIOTHERAPY; PATIENT HISTORY OF TUMORECTOMY; PREDICTION; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SEVERE NEUTROPENIA; THERAPY DELAY; ADVERSE EFFECTS; AGE; CHEMICALLY INDUCED; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOTHERAPY; RISK FACTORS; TAXOIDS;

EID: 84930670611     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0746-7     Document Type: Article

References (18)

1. American Cancer Society (ACS) (2013) Cancer facts and figures 2013. http://www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&level=1. Accessed Jan 2013
2. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
3. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520
4. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154
5. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148
6. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93
7. Smith TJ (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205
8. Crawford J, Allen J, Armitage J et al (2011) Myeloid gowth factors. J Natl Compr Cancer Netw 9:914–932
9. Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465
10. Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195–202
11. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38(5):365–372
12. Nishimura K, Nonomura N, Hashine K et al (2013) Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. Int J Clin Oncol 18(2):306–313
13. Laskey RA, Poniewierski MS, Lopez MA et al (2012) Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 125(3):625–630
14. Hosmer W, Malin J, Wong M (2011) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19(3):333–341
15. Kellokumpu-Lehtinen PL, Hjalm-Eriksson M, Thellenberg-Karlsson C et al (2012) Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Prostate Cancer Prostatic Dis 15(3):303–307
16. Shiozawa T, Tadokoro JI, Fujiki T et al (2013) Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43(5):483–491
17. Jiang N, Chen XC, Zhao Y (2013) Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer. Support Care Cancer 21(3):785–791
18. Intragumtornchai T, Sutheesophon J, Sutcharitchan P et al (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-hodgkin’s lymphoma. Leuk Lymphoma 37(3–4):351–360